Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Moodys
Chubb
QuintilesIMS
Boehringer Ingelheim
Chinese Patent Office
Cerilliant
Federal Trade Commission
AstraZeneca

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,280,959

« Back to Dashboard

Which drugs does patent 6,280,959 protect, and when does it expire?

Patent 6,280,959 protects PROMACTA and is included in two NDAs.

Protection for PROMACTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-two patent family members in seven countries.
Summary for Patent: 6,280,959
Title: Metal complexes
Abstract:The invention describes zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, methods of using these compounds as agonist of dimeric cell-surface receptors. Novel processes used in preparing the compounds are also described. Further, the invention describes novel receptor binding moieties of the zinc chelated cell-surface receptor ligands.
Inventor(s): Gleason; John G. (Downingtown, PA), Luengo; Juan I. (Audubon, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/530,307
Patent Claim Types:
see list of patent claims
Use; Process; Composition; Compound;

Drugs Protected by US Patent 6,280,959

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp PROMACTA eltrombopag olamine FOR SUSPENSION;ORAL 207027-001 Aug 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-004 Oct 20, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-001 Nov 20, 2008 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-002 Nov 20, 2008 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,280,959

PCT Information
PCT FiledOctober 30, 1998PCT Application Number:PCT/US98/23186
PCT Publication Date:May 14, 1999PCT Publication Number: WO99/22732

Non-Orange Book US Patents Family Members for Patent 6,280,959

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,211,200 Metal complexes ➤ Try a Free Trial
6,413,952 Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,280,959

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain 2301215 ➤ Try a Free Trial
Spain 2284217 ➤ Try a Free Trial
European Patent Office 1039906 ➤ Try a Free Trial
European Patent Office 1032388 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Federal Trade Commission
UBS
Healthtrust
Daiichi Sankyo
Queensland Health
Accenture
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.